November 18, 2026
Globus Medical missed third quarter revenue and flagged weakness at its Nevro unit, sending the shares sharply lower on a day of building market stress.
What happened
Globus Medical shares moved 2.1 percent, a drop bigger than 78 percent of its daily moves over three years. The company reported third quarter earnings that missed revenue expectations and cut guidance. Management specifically highlighted softness in the Nevro business it acquired.
Why it matters
The miss raises doubts about the Nevro integration which was meant to broaden Globus’s reach in neuromodulation. When a roughly 100-billion-dollar market value cohort feels pressure from a sector bellwether cutting its outlook, the weakness can spill onto peers who face the same procedural volume trends.
The case against
A single quarter miss driven by a discrete acquisition’s growing pains may say little about the core spine business. If procedure volumes rebound and Nevro’s pipeline gains traction, the reset in expectations could prove temporary.
What settles it
Whether procedure volumes stabilize next quarter and whether peers report the same softness in neuromodulation.